anonymous
Guest
anonymous
Guest
Poll: Many Americans concerned about FDA process for Alzheimer's drug
A new survey from STAT and the Harris Poll finds that two-thirds of those familiar with Biogen's Alzheimer's drug Aduhelm believe it will be effective. This number dropped to about half among those who had only heard of the approval but were not as informed on the details behind the drug. The survey, which queried more than 2,100 U.S. adults between June 11 and June 13, also found that people were divided over the price of the drug (estimated to be $56,000 a year before insurance or other discounts) and that respondents were concern about the regulatory process behind the drug's approval, since the FDA granted Aduhelm an "accelerated approval" based on surrogate endpoints. The findings highlight the ongoing controversy over the approval of Aduhelm, especially as physicians and payers now weigh how to work with the drug. Read more here.
A new survey from STAT and the Harris Poll finds that two-thirds of those familiar with Biogen's Alzheimer's drug Aduhelm believe it will be effective. This number dropped to about half among those who had only heard of the approval but were not as informed on the details behind the drug. The survey, which queried more than 2,100 U.S. adults between June 11 and June 13, also found that people were divided over the price of the drug (estimated to be $56,000 a year before insurance or other discounts) and that respondents were concern about the regulatory process behind the drug's approval, since the FDA granted Aduhelm an "accelerated approval" based on surrogate endpoints. The findings highlight the ongoing controversy over the approval of Aduhelm, especially as physicians and payers now weigh how to work with the drug. Read more here.